BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

DISEASE CATEGORY: Cancer INDICATION: Sarcoma A pyrido-indole-based tool compound that triggers degradation of MDM2, an enzyme that suppresses p53 expression, could treat liposarcoma. In 10 human liposarcoma cell lines, the compound inhibited growth with IC...
BioCentury | Jul 23, 2020
Emerging Company Profile

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb  In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and...
BioCentury | May 29, 2020
Distillery Therapeutics

The mitochondrial peptidase NLN identified as AML target

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Inhibiting the mitochondrial peptidase NLN could treat AML and other leukemias. NLN protein levels were higher in the mitochondria of patient-derived primary AML cells than in the...
BioCentury | May 29, 2020
Distillery Therapeutics

Inhibitors of an orphan nuclear receptor for prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Small molecule inhibitors of NR2F2, an orphan nuclear receptor, could treat prostate cancer. High throughput screening of >370,000 compounds for NR2F2 inhibitors yielded two dimethoxybenzene-based molecules that blocked the...
BioCentury | Apr 2, 2020
Distillery Therapeutics

CDC42BPA inhibition for high-grade serous ovarian carcinoma

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Inhibition of CDC42BPA alone or in combination with carboplatin and PAK1 inhibition could treat high-grade serous ovarian carcinoma (HGSOC). Among 594 patient tumors, 44% of the samples had genomic...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Base editor correction of TERT promoter mutations for glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Gene editing with a CRISPR base editor to correct mutations in the TERT promoter could treat gliomas harboring those mutations. An adeno-associated virus serotype 2 (AAV2) vector delivering an...
BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); breast cancer; small cell lung cancer A University of Florida team led by Dialectic Therapeutics Inc. co-founders Guangrong Zheng and Daohong Zhou showed the company’s lead candidate,...
BC Innovations | Dec 18, 2019
Distillery Therapeutics

The proteasome-regulating kinase DYRK2 as a target in breast cancer and multiple myeloma

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; multiple myeloma (MM) Inhibiting the proteasome-regulating kinase DYRK2 could treat breast cancer and MM. In patients with triple-negative breast cancer (TNBC) or MM, DYRK2 expression and protein levels were...
BC Innovations | Dec 12, 2019
Distillery Therapeutics

Combined inhibition of CDK12 and CDK13 for TNBC

DISEASE CATEGORY: Cancer INDICATION: Breast cancer A Moffitt Cancer Center and Research Institute team showed that dual inhibition of CDK12 and CDK13 could treat triple-negative breast cancer (TNBC). In four human TNBC cell lines, an...
Items per page:
1 - 10 of 210